A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Researchers evaluated outcomes in a cohort of patients in the phase 3b randomized VISIBLE trial, which included 102 adults with skin of color and scalp psoriasis (mean age, 42.5 years; Fitzpatrick ...

Discover a study that found that following surgery, 97.2% of patients experienced a reduction in psoriasis severity to mild ...

Five of those studies reported improvement in psoriasis area and severity index scoring after 8 or 12 weeks of meditation or mindfulness interventions. Two of the trials demonstrated psychological ...

Patients who received oral tranexamic acid 500 mg daily for 3 months had reduced melasma severity and systemic inflammation markers.

Psoriasis is a chronic skin disorder characterized by epidermal hyperproliferation and dermal inflammation that vary in severity, from minor, localized patches to complete body coverage. It ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to find out why I rate PTGX is a Buy.

U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

Those include having a Psoriasis Area and Severity Index (PASI) of 10 or more – indicating that lesions cover at least 10% of their body – and a Dermatology Life Quality Index (DLQI) score ...

Patients with psoriatic arthritis (PsA) have a higher prevalence of diabetes mellitus (DM) compared to the general population ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.